Meiji Yasuda Asset Management CO Ltd. Neurocrine Biosciences Inc Transaction History
Meiji Yasuda Asset Management CO Ltd.
- $2.56 Billion
- Q4 2024
A detailed history of Meiji Yasuda Asset Management CO Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Meiji Yasuda Asset Management CO Ltd. holds 7,260 shares of NBIX stock, worth $848,331. This represents 0.04% of its overall portfolio holdings.
Number of Shares
7,260
Previous 7,260
-0.0%
Holding current value
$848,331
Previous $835,000
18.56%
% of portfolio
0.04%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding NBIX
# of Institutions
636Shares Held
94.2MCall Options Held
634KPut Options Held
603K-
Black Rock Inc. New York, NY14.2MShares$1.66 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.18 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$602 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$301 Million0.47% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$219 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...